These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22627466)

  • 1. Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic.
    Wang H; Wang L; Cao K; Emanuel SL; Morin P; Lin Z; Shen G; Hosbach J; Zhang D; Bonacorsi S; Rodrigues AD; Yang Z
    Drug Metab Dispos; 2012 Sep; 40(9):1677-85. PubMed ID: 22627466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
    Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
    J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.
    Yang Z; Sun X; Li S; Tan Y; Wang X; Zhang N; Yagi S; Takakura T; Kobayashi Y; Takimoto A; Yoshioka T; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Aug; 64(16):5775-8. PubMed ID: 15313919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).
    Han JM; Myung H; Kim S
    Cancer Lett; 2010 Jan; 287(2):157-64. PubMed ID: 19573982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.
    Zhao H; Peng P; Longley C; Zhang Y; Borowski V; Mehlig M; Reddy P; Xia J; Borchard G; Lipman J; Benimetskaya L; Stein CA
    J Control Release; 2007 Jun; 119(2):143-52. PubMed ID: 17397960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective uptake of the anticancer drug bendamustine by liver and kidney tissues following its intravenous administration to mice.
    Bezek S; Kukan M; Scasnár V; Lukácsová M; Trnovec T
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):117-22. PubMed ID: 8740243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
    Takakura T; Takimoto A; Notsu Y; Yoshida H; Ito T; Nagatome H; Ohno M; Kobayashi Y; Yoshioka T; Inagaki K; Yagi S; Hoffman RM; Esaki N
    Cancer Res; 2006 Mar; 66(5):2807-14. PubMed ID: 16510603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects.
    Kim TH; Youn YS; Jiang HH; Lee S; Chen X; Lee KC
    Bioconjug Chem; 2011 Aug; 22(8):1631-7. PubMed ID: 21751817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated D-amino acid oxidase.
    Fang J; Deng D; Nakamura H; Akuta T; Qin H; Iyer AK; Greish K; Maeda H
    Int J Cancer; 2008 Mar; 122(5):1135-44. PubMed ID: 17990314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
    Yang C; Liu HZ; Lu WD; Fu ZX
    Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
    Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
    Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.
    Huang FY; Mei WL; Li YN; Tan GH; Dai HF; Guo JL; Wang H; Huang YH; Zhao HG; Zhou SL; Li L; Lin YY
    Eur J Cancer; 2012 Sep; 48(14):2260-9. PubMed ID: 22257793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
    Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
    Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
    Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
    J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.